clinical trial · NCT06202027
Post Marketing Surveillance Study to Observe Safety and Effectiveness of CRYSVITA® in S. Korean Patients
Kyowa Kirin Korea Co., Ltd.·—·recruiting·n = 100
FGF23-related Hypophosphataemic Rickets and OsteomalaciaFGF23-related hypophosphataemic rickets and osteomalacia
brief summary
The objective of this post-marketing surveillance (PMS) study is to assess the safety and effectiveness of CRYSVITA injection 10, 20, and 30mg, equivalent to in routine clinical settings
started
Aug 11, 2023
primary completion
Jun 16, 2031
completion
Jul 16, 2031
last updated
Aug 29, 2025
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol